<DOC>
	<DOCNO>NCT02792686</DOCNO>
	<brief_summary>This study open label , parallel group , single ascend dose , exploratory study perform single site ( Centre Cap , Montpellier , France ) .</brief_summary>
	<brief_title>ABX464 First Man Study</brief_title>
	<detailed_description>This study open label , parallel group , single ascend dose , exploratory study perform single site ( Centre Cap , Montpellier , France ) . Six subject per dose group enrol 1 4 group escalate dos ABX464 ( 50 , 100 , 150 200 mg ) . For dose group , first subject treat , adverse event ( AE ) occur , second subject dose one hour later . The four last subject dose day clinically significant AE occur . Escalation follow dose level decide review PK safety data ( laboratory result , ECG , vital sign AEs )</detailed_description>
	<criteria>Healthy volunteer Subject good health basis medical history , physical examination , vital sign , electrocardiogram ( ECG ) routine laboratory safety test Subject BMI 18 27kg/mÂ² Non smoker light smoker less 10 cigarette per day Having give write informed consent Subject ongoing infection disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>